IDEXX Laboratories Announces Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 13% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
IDEXX Labs (IDXX) Tops Q3 EPS by 8c; Raises FY18 EPS Outlook, Maintains FY18 Revenue Guidance, Offers Prelim. FY19 EPS/Revenue Views
November 1, 2018 6:41 AM EDT(Updated - November 1, 2018 6:56 AM EDT)
(Update corrects consensus revenue figure)
IDEXX Labs (NASDAQ: IDXX) reported Q3 EPS of $1.05, $0.08 better than the analyst estimate of $0.97. Revenue for the quarter came in at $545.45 million versus the consensus estimate of $545.49 million.
Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organicDelivers EPS of $1.05, a 33% increase year-over-year on a reported basis or 39% on a comparable constant currency basisRefines 2018 reported revenue guidance to $2,205 billion - $2,215... More